Phase 1/2 trial of talazoparib in combination with temozolomide in children and adolescents with refractory/recurrent solid tumors including Ewing sarcoma: A Children's Oncology Group Phase 1 Consortium study (ADVL1411)

Risk stratification by somatic mutation burden in Ewing sarcoma

(2019) Kevin X. Liu et al.   CANCER

Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial

(2018) J Ettl et al.   ANNALS OF ONCOLOGY

Ewing-like sarcoma: An emerging family of round cell sarcomas

(2018) Samuele Renzi et al.   JOURNAL OF CELLULAR PHYSIOLOGY

EWS–FLI1 increases transcription to cause R-loops and block BRCA1 repair in Ewing sarcoma

(2018) Aparna Gorthi et al.   NATURE

Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation

(2018) Jennifer K. Litton et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Ewing Family of Tumors Relies on BCL-2 and BCL-XL to Escape PARP Inhibitor Toxicity

(2018) Daniel A.R. Heisey et al.   CLINICAL CANCER RESEARCH

Restricted Delivery of Talazoparib Across the Blood–Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma

(2017) Sani H. Kizilbash et al.   MOLECULAR CANCER THERAPEUTICS

Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers

(2017) Johann de Bono et al.   Cancer Discovery

PARP Inhibitors Sensitize Ewing Sarcoma Cells to Temozolomide-Induced Apoptosis via the Mitochondrial Pathway

(2015) F. Engert et al.   MOLECULAR CANCER THERAPEUTICS

NKD2, a negative regulator of Wnt signaling, suppresses tumor growth and metastasis in osteosarcoma

(2015) S Zhao et al.   ONCOGENE

Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy

(2014) Edwin Choy et al.   BMC CANCER

Synergistic Activity of PARP Inhibition by Talazoparib (BMN 673) with Temozolomide in Pediatric Cancer Models in the Pediatric Preclinical Testing Program

(2014) M. A. Smith et al.   CLINICAL CANCER RESEARCH

A phase I trial of veliparib (ABT-888) and temozolomide in children with recurrent CNS tumors: a Pediatric Brain Tumor Consortium report†

(2014) Jack M. Su et al.   NEURO-ONCOLOGY

Genomic Landscape of Ewing Sarcoma Defines an Aggressive Subtype with Co-Association of STAG2 and TP53 Mutations

(2014) F. Tirode et al.   Cancer Discovery

Targeting the DNA Repair Pathway in Ewing Sarcoma

(2014) Elizabeth Stewart et al.   Cell Reports

The Genomic Landscape of the Ewing Sarcoma Family of Tumors Reveals Recurrent STAG2 Mutation

(2014) Andrew S. Brohl et al.   PLoS Genetics

BMN 673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency

(2013) Y. Shen et al.   CLINICAL CANCER RESEARCH

Glioblastoma Cells Containing Mutations in the Cohesin Component STAG2 Are Sensitive to PARP Inhibition

(2013) M. L. Bailey et al.   MOLECULAR CANCER THERAPEUTICS

Advances in using PARP inhibitors to treat cancer

(2012) Shivaani Kummar et al.   BMC Medicine

PARP-1 Inhibition as a Targeted Strategy to Treat Ewing's Sarcoma

(2012) J. C. Brenner et al.   CANCER RESEARCH

Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors

(2012) J. Murai et al.   CANCER RESEARCH

Predicting Enhanced Cell Killing through PARP Inhibition

(2012) J. K. Horton et al.   MOLECULAR CANCER RESEARCH

Systematic identification of genomic markers of drug sensitivity in cancer cells

(2012) Mathew J. Garnett et al.   NATURE

Mechanistic Rationale for Inhibition of Poly(ADP-Ribose) Polymerase in ETS Gene Fusion-Positive Prostate Cancer

(2011) J. Chad Brenner et al.   CANCER CELL

The use and effectiveness of temozolomide in children with central nervous system tumours: a survey from the Canadian Paediatric Brain Tumour Consortium

(2011) U. Bartels et al.   Current Oncology

Temozolomide in the treatment of high-grade gliomas in children: a report from the Children's Oncology Group

(2011) K. J. Cohen et al.   NEURO-ONCOLOGY

Elevated expression of CXC chemokines in pediatric osteosarcoma patients

(2010) Yiting Li et al.   CANCER

53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers

(2010) Peter Bouwman et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Pharmacokinetics of temozolomide administered in combination with O6-benzylguanine in children and adolescents with refractory solid tumors

(2009) Holly J. Meany et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER